Modeling the progression of neuropsychiatric symptoms in Alzheimer's disease with PET-based Braak staging.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: United States NLM ID: 8100437 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-1497 (Electronic) Linking ISSN: 01974580 NLM ISO Abbreviation: Neurobiol Aging Subsets: MEDLINE
    • Publication Information:
      Publication: New York : Elsevier
      Original Publication: Fayetteville, N.Y. : Ankho International.
    • Subject Terms:
      Alzheimer Disease*/pathology ; Alzheimer Disease*/diagnostic imaging ; Alzheimer Disease*/psychology ; Disease Progression* ; Positron-Emission Tomography* ; tau Proteins*/metabolism; Humans ; Female ; Male ; Aged ; Aged, 80 and over ; Brain/pathology ; Brain/diagnostic imaging ; Severity of Illness Index
    • Abstract:
      In Alzheimer's disease (AD), neuropsychiatric symptoms (NPS) correlate with tau deposition in the brain. Here, we investigated the association of PET-based Braak stages with NPS and assessed whether they predict annual changes in NPS. We evaluated 231 individuals in the aging and AD continuum. Participants were assigned a Braak stage at baseline and followed for 1.97 (s.d. 0.62) years. NPS were investigated using the Mild Behavioral Impairment Checklist (MBI-C) and the Neuropsychiatric Inventory Questionnaire severity (NPI-Q-S) and distress (NPI-Q-D) scales. Multiple linear regressions (MLR) assessed the association of Braak stages with baseline NPS and the annual change in NPS scores. At baseline, stages I-II, III-IV, and V-VI were associated with higher MBI-C, NPI-Q-S, and NPI-Q-D scores. Stages V-VI were associated with a significant annual increase in MBI-C scores. These findings suggest that tau accumulation may manifest clinically with an increase in NPS, which seems to be an early event in AD pathophysiology. Moreover, PET-based Braak staging appears to be a good predictor of NPS severity progression.
      Competing Interests: Declaration of Interest E.R.Z. serves on the scientific advisory board of Next Innovative Therapeutics. Z.I. has served as an advisor/consultant to CADTH, Eisai, Eli Lilly, Lundbeck/Otsuka, Novo Nordisk, and Roche. S.G. has served as a scientific advisor to Cerveau Therapeutics. Outside the work presented in this paper, P.R.N. provides consultancy services for Roche, Cerveau Radiopharmaceuticals, Lilly, Eisai, Pfizer, and Novo Nordisk. P.R.N. also serves as a clinical trials investigator for Biogen and Novo Nordisk. The other authors declare that they have no competing interests.
      (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Alzheimer's disease; Braak staging; Dementia; Neurofibrillary tangles; Neuropsychiatric symptom; Positron emission tomography
    • Accession Number:
      0 (tau Proteins)
    • Publication Date:
      Date Created: 20240926 Date Completed: 20241019 Latest Revision: 20241019
    • Publication Date:
      20241020
    • Accession Number:
      10.1016/j.neurobiolaging.2024.09.009
    • Accession Number:
      39326302